kabutan

Sumitomo Pharma Co., Ltd.(4506) Summary

4506
TSE Prime
Sumitomo Pharma Co., Ltd.
2,242.5
JPY
-68.5
(-2.96%)
Dec 12, 3:30 pm JST
14.39
USD
Dec 12, 1:30 am EST
Result
PTS
outside of trading hours
2,228
Dec 12, 11:54 pm JST
Summary Chart Historical News Financial Result
PER
9.6
PBR
3.35
Yield
ー%
Margin Trading Ratio
4.82
Stock Price
Dec 12, 2025
Opening Dec 12, 9:00 am
2,318.0 JPY 14.90 USD
Previous Close Dec 11
2,311.0 JPY 14.80 USD
High Dec 12, 9:00 am
2,350.0 JPY 15.11 USD
Low Dec 12, 1:40 pm
2,198.5 JPY 14.12 USD
Volume
11,243,400
Trading Value
0.03T JPY 0.16B USD
VWAP
2259.14 JPY 14.5 USD
Minimum Trading Value
224,250 JPY 1,439 USD
Market Cap
0.89T JPY 5.76B USD
Number of Trades
31,579
Liquidity & Number of Trades
As of Dec 12, 2025
Liquidity
High
1-Year Average
9,089
1-Year High Nov 5, 2025
69,972
Margin Trading
Date Short Interest Long Margin Positions Ratio
Dec 5, 2025 640,800 7,279,100 11.36
Nov 28, 2025 912,100 6,424,100 7.04
Nov 21, 2025 898,700 6,571,500 7.31
Nov 14, 2025 946,000 6,296,500 6.66
Nov 7, 2025 775,800 6,763,500 8.72
Company Profile
Sumitomo Pharma Co., Ltd. is a mid-sized pharmaceutical company originating from the Sumitomo Chemical group. The company focuses on developing drugs in the areas of psychiatry and neurology, oncology, and regenerative medicine.
Sector
Pharmaceuticals
Sumitomo Pharma's core business is the manufacturing, procurement, and sales of prescription pharmaceuticals, while also dealing with medical devices. The company prioritizes psychiatry, neurology, and oncology as its key therapeutic areas. In Japan, Sumitomo Pharma conducts manufacturing and sales of prescription pharmaceuticals through its subsidiaries. Additionally, through a joint venture with its parent company Sumitomo Chemical, it engages in contract development and manufacturing in the field of regenerative medicine and cell therapy. Sumitomo Pharma is also actively expanding globally, with operations in North America, China, Southeast Asia, and Taiwan. The company has established subsidiaries in various regions to conduct local pharmaceutical manufacturing, sales, and information provision activities.